Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Celcuity (Nasdaq: CELC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, March 25, 2026.

Rhea-AI Summary

Celcuity (Nasdaq: CELC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, March 25, 2026. Management will host a webcast/teleconference at 4:30 p.m. ET the same day to discuss results and provide a corporate update.

Domestic dial-in is 1-800-717-1738, international dial-in is 1-646-307-1865, and a live webcast is available via the company link; a replay will be posted on Celcuity's website.

Argus Mar 18 session

-1.40% close to close Open Argus

Details

News Market Reaction – CELC

In the Mar 18 session, CELC declined 1.40%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for the release of fourth quarter and full year 2025 results and...

Analysis

This announcement sets expectations for the release of fourth quarter and full year 2025 results and a same-day webcast at 4:30 p.m. ET. Historically, similar scheduling notices under the “conferences,earnings” tag have produced only modest single-day moves, with an average reaction of about 0.59%. Investors may focus on how upcoming results intersect with Celcuity’s clinical progress and its effective $400,000,000 shelf and at-the-market program when the detailed financials and corporate update are provided.

Key Figures

Results date: March 25, 2026 Webcast time: 4:30 p.m. Eastern Time Domestic dial-in: 1-800-717-1738 +5 more

Results date

March 25, 2026

Q4 and full year 2025 financial results release after market close

Webcast time

4:30 p.m. Eastern Time

Scheduled start of management webcast/teleconference

Domestic dial-in

1-800-717-1738

U.S. access number for the conference call

International dial-in

1-646-307-1865

International access number for the conference call

PDUFA goal date

July 17, 2026

Previously disclosed FDA Priority Review date for gedatolisib

ATM capacity

$400,000,000

Common stock that may be sold via at-the-market program under S-3ASR

Current share price

$114.11

Price before Q4/FY25 scheduling announcement

52-week range

$7.575–$120.315

Low and high over the last 52 weeks prior to this news

Previous Conferences,earnings Reports

5 past events · Latest: Nov 05

Same Type 5 events

1. Nov 05

   Q3 2025 scheduling

   24h Move

   +2.2%

   Announced Q3 2025 results release date and post-close webcast details.

2. Aug 07

   Q2 2025 scheduling

   24h Move

   +0.1%

   Set date and access details for Q2 2025 results and webcast.

3. May 07

   Q1 2025 scheduling

   24h Move

   +0.6%

   Outlined timing and dial-in for Q1 2025 financial results call.

4. Mar 24

   FY 2024 scheduling

   24h Move

   +3.2%

   Announced Q4 and full-year 2024 release with same-day webcast.

5. Nov 07

   Q3 2024 scheduling

   24h Move

   -3.2%

   Scheduled Q3 2024 results release and webcast timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1751140&tp_key=9ff20687c4. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer (“ABC”), has completed enrollment, and the company has reported detailed results for the PIK3CA wild-type cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with endocrine resistant HR+/HER2- ABC, is ongoing. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com  
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Celcuity (CELC) release Q4 and full year 2025 results?

Celcuity will release Q4 and full year 2025 results after market close on March 25, 2026. According to the company, management will discuss the results during a 4:30 p.m. ET webcast/teleconference that same day and provide a corporate update.

How can investors join the Celcuity (CELC) webcast/teleconference on March 25, 2026?

Investors can join the Celcuity webcast at 4:30 p.m. ET via the provided webcast link or by phone. According to the company, domestic callers dial 1-800-717-1738 and international callers dial 1-646-307-1865 to participate in the teleconference.

Will a replay of the Celcuity (CELC) March 25, 2026 webcast be available?

Yes, a replay will be available on Celcuity's website after the live event. According to the company, a recorded webcast presentation and replay will be posted following the conclusion of the teleconference for later access.

What topics will Celcuity (CELC) management address in the March 25, 2026 call?

Management will discuss the fourth quarter and full year 2025 financial results and provide a corporate update. According to the company, the webcast/teleconference is intended to review results and update investors on recent clinical and corporate developments.

Is there a direct webcast link to join Celcuity's (CELC) March 25, 2026 presentation?

Yes, a live webcast link is provided for the March 25, 2026 presentation. According to the company, participants can access the webcast using the supplied URL and listen to the live presentation and subsequent Q&A.

Are international callers able to join the Celcuity (CELC) teleconference on March 25, 2026?

Yes, international callers can join by dialing 1-646-307-1865 for the March 25, 2026 teleconference. According to the company, this number is provided alongside a domestic dial-in and a live webcast for global participation.